Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PHR -25.4%, TE -16.3%, JFIN -2.7%, CEG -2.4% (guidance), ANNA -2.3%, HDL -2%, ALTI -1.7%
Other news:
- PEPG -42.1% (topline results from lowest dose (5 mg/kg) MAD cohort in the ongoing Phase 2 FREEDOM2 Study)
- SVC -17.3% (stock offering)
- IONR -15.2% (secures court ruling upholding permit for Rhyolite Ridge project)
- SATL -10.7% (entered into $50 mln Sales Agreement)
- TRMK -7.3% (names new CFO and COO)
- PALI -2.8% (topline data from phase 1b clinical study of PALI-2108)
- JBSS -2.2% (declares special cash dividend of $1.50/share)
- MTB -2% (authorizes new $5 bln share repurchase program)
- BIIB -1.5% (Apellis Pharmaceuticals to be acquired by Biogen (BIIB) for $41.00/share in cash at closing)